Trial Watch: Adoptive cell transfer for oncological indications

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Aranda, Fernando ^a   Buqué, Aitziber ^b,c   Bloy, Norma ^b,c   Castoldi, Francesca ^c,d,e   Eggermont, Alexander ^b   Cremer, Isabelle ^c,f   Fridman, Wolf Hervé ^c,f   Fucikova, Jitka ^e,g   Galon, Jérôme ^c,f,h   Spisek, Radek ^e,g   Tartour, Eric ^h,i,j   Zitvogel, Laurence ^b,k   Kroemer, Guido ^b,c,f,h,j   Galluzzi, Lorenzo ^b,c,f,h  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e Sotio as   (Czech Republic)

^f SORBONNE UNIVERSITÉ   (France)

^g CHARLES UNIVERSITY   (Czech Republic)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k INSERM   (France)

more..

Author keywords

checkpoint blockers; chimeric antigen receptor; GM CSF; TCR; TLR agonists; tumor associated antigens

Indexed keywords

B CELL MATURATION ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYPICAN; MELANOMA ANTIGEN 3; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; THYROGLOBULIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CARCINOMA; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TUMOR ASSOCIATED LEUKOCYTE;

EID: 84941772232     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1046673     Document Type: Article

References (179)

1. S.A.Rosenberg, N.P.Restifo. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348:62-8; PMID:25838374; http://dx.doi.org/10.1126/science.aaa4967
2. C.H.June, S.R.Riddell, T.N.Schumacher. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015; 7:280ps7; PMID:25810311; http://dx.doi.org/10.1126/scitranslmed.aaa3643
3. J.A.Bluestone, Q.Tang. Immunotherapy: making the case for precision medicine. Sci Transl Med 2015; 7:280ed3; PMID:25810308; http://dx.doi.org/10.1126/scitranslmed.aaa9846
4. N.P.Restifo, M.E.Dudley, S.A.Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
5. S.A.Rosenberg. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116
6. S.A.Rosenberg, N.P.Restifo, J.C.Yang, R.A.Morgan, M.E.Dudley. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
7. R.Kirk. Immunotherapy: adoptive cell therapy simplified. Nat Rev Clin Oncol 2013; 10:368; PMID:23689751; http://dx.doi.org/10.1038/nrclinonc.2013.85
8. C.Humphries. Adoptive cell therapy: honing that killer instinct. Nature 2013; 504:S13-5; PMID:24352359; http://dx.doi.org/10.1038/504S13a
9. M.V.Maus, J.A.Fraietta, B.L.Levine, M.Kalos, Y.Zhao, C.H.June. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32:189-225; PMID:24423116; http://dx.doi.org/10.1146/annurev-immunol-032713-120136
10. R.R.Jenq, M.R.van den Brink. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10:213-21; PMID:20168320; http://dx.doi.org/10.1038/nrc2804
11. F.Barriga, P.Ramirez, A.Wietstruck, N.Rojas. Hematopoietic stem cell transplantation: clinical use and perspectives. Biol Res 2012; 45:307-16; PMID:23283440; http://dx.doi.org/10.4067/S0716-97602012000300012
12. C.McDonald-Hyman, L.A.Turka, B.R.Blazar. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med 2015; 7:280rv2; PMID:25810312; http://dx.doi.org/10.1126/scitranslmed.aaa6853
13. L.Galluzzi, L.Senovilla, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautès-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
14. E.Vacchelli, I.Vitale, A.Eggermont, W.H.Fridman, J.Fucikova, I.Cremer, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi.org/10.4161/onci.25771
15. K.Palucka, J.Banchereau. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
16. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
17. L.Galluzzi, E.Vacchelli, J.M.Bravo-San Pedro, A.Buque, L.Senovilla, E.E.Baracco, N.Bloy, F.Castoldi, J.P.Abastado, P.Agostinis et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519
18. F.Pages, A.Berger, M.Camus, F.Sanchez-Cabo, A.Costes, R.Molidor, B.Mlecnik, A.Kirilovsky, M.Nilsson, D.Damotte et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
19. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pages, M.Tosolini, M.Camus, A.Berger, P.Wind et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
20. B.Mlecnik, M.Tosolini, A.Kirilovsky, A.Berger, G.Bindea, T.Meatchi, P.Bruneval, Z.Trajanoski, W.H.Fridman, F.Pagès et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
21. J.Galon, H.K.Angell, D.Bedognetti, F.M.Marincola. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008
22. G.Bindea, B.Mlecnik, M.Tosolini, A.Kirilovsky, M.Waldner, A.C.Obenauf, H.Angell, T.Fredriksen, L.Lafontaine, A.Berger et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
23. J.Galon, B.Mlecnik, G.Bindea, H.K.Angell, A.Berger, C.Lagorce, A.Lugli, I.Zlobec, A.Hartmann, C.Bifulco et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi.org/10.1002/path.4287
24. Y.S.Yun, M.E.Hargrove, C.C.Ting. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49:4770-4; PMID:2527087
25. R.Bouquie, A.Bonnin, K.Bernardeau, A.Khammari, B.Dreno, F.Jotereau, N.Labarrière, F.Lang. A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother 2009; 58:553-66; PMID:18751701; http://dx.doi.org/10.1007/s00262-008-0578-2
26. J.A.Chacon, S.Pilon-Thomas, A.A.Sarnaik, L.G.Radvanyi. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2013; 2:e25581; PMID:24319633; http://dx.doi.org/10.4161/onci.25581
27. A.Chhabra, L.Yang, P.Wang, B.Comin-Anduix, R.Das, N.G.Chakraborty, S.Ray, S.Mehrotra, H.Yang, C.L.Hardee et al. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol 2008; 181:1063-70; PMID:18606658; http://dx.doi.org/10.4049/jimmunol.181.2.1063
28. S.Ray, A.Chhabra, N.G.Chakraborty, U.Hegde, D.I.Dorsky, T.Chodon, E.von Euw, B.Comin-Anduix, R.C.Koya, A.Ribas et al. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol 2010; 136:338-47; PMID:20547105; http://dx.doi.org/10.1016/j.clim.2010.04.013
29. M.Sadelain, I.Riviere, R.Brentjens. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3:35-45; PMID:12509765; http://dx.doi.org/10.1038/nrc971
30. P.F.Robbins, R.A.Morgan, S.A.Feldman, J.C.Yang, R.M.Sherry, M.E.Dudley, J.R.Wunderlich, A.V.Nahvi, L.J.Helman, C.L.Mackall et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-24; PMID:21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537
31. M.Sadelain, R.Brentjens, I.Riviere. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-98; PMID:23550147; http://dx.doi.org/10.1158/2159-8290.CD-12-0548
32. G.Dotti, S.Gottschalk, B.Savoldo, M.K.Brenner. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257:107-26; PMID:24329793; http://dx.doi.org/10.1111/imr.12131
33. M.C.Jensen, S.R.Riddell. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014; 257:127-44; PMID:24329794; http://dx.doi.org/10.1111/imr.12139
34. D.L.Porter, B.L.Levine, M.Kalos, A.Bagg, C.H.June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
35. J.N.Kochenderfer, S.A.Rosenberg. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10:267-76; PMID:23546520; http://dx.doi.org/10.1038/nrclinonc.2013.46
36. A.H.Long, W.M.Haso, R.J.Orentas. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology 2013; 2:e23621; PMID:23734316; http://dx.doi.org/10.4161/onci.23621
37. P.Spear, A.Barber, C.L.Sentman. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology 2013; 2:e23564; PMID:23734311; http://dx.doi.org/10.4161/onci.23564
38. J.N.Kochenderfer, M.E.Dudley, S.A.Feldman, W.H.Wilson, D.E.Spaner, I.Maric, M.Stetler-Stevenson, G.Q.Phan, M.S.Hughes, R.M.Sherry et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388
39. J.N.Kochenderfer, W.H.Wilson, J.E.Janik, M.E.Dudley, M.Stetler-Stevenson, S.A.Feldman, I.Maric, M.Raffeld, D.A.Nathan, B.J.Lanier et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099-102; PMID:20668228; http://dx.doi.org/10.1182/blood-2010-04-281931
40. J.N.Kochenderfer, Z.Yu, D.Frasheri, N.P.Restifo, S.A.Rosenberg. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-86; PMID:20631379; http://dx.doi.org/10.1182/blood-2010-01-265041
41. R.J.Brentjens, I.Riviere, J.H.Park, M.L.Davila, X.Wang, J.Stefanski, C.Taylor, R.Yeh, S.Bartido, O.Borquez-Ojeda et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817-28; PMID:21849486; http://dx.doi.org/10.1182/blood-2011-04-348540
42. M.Kalos, B.L.Levine, D.L.Porter, S.Katz, S.A.Grupp, A.Bagg, C.H.June. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
43. B.Savoldo, C.A.Ramos, E.Liu, M.P.Mims, M.J.Keating, G.Carrum, R.T.Kamble, C.M.Bollard, A.P.Gee, Z.Mei et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-6; PMID:21540550; http://dx.doi.org/10.1172/JCI46110
44. R.J.Brentjens, M.L.Davila, I.Riviere, J.Park, X.Wang, L.G.Cowell, S.Bartido, J.Stefanski, C.Taylor, M.Olszewska et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
45. T.Gruber, R.Hinterleitner, C.Pfeifhofer-Obermair, D.Wolf, G.Baier. Engineering effective T-cell based antitumor immunity. Oncoimmunology 2013; 2:e22893; PMID:23525844; http://dx.doi.org/10.4161/onci.22893
46. E.Merhavi-Shoham, A.Haga-Friedman, C.J.Cohen. Genetically modulating T-cell function to target cancer. Semin Cancer Biol 2012; 22:14-22; PMID:22210183; http://dx.doi.org/10.1016/j.semcancer.2011.12.006
47. K.Liu, S.A.Rosenberg. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167:6356-65; PMID:11714800; http://dx.doi.org/10.4049/jimmunol.167.11.6356
48. J.Zhou, X.Shen, J.Huang, R.J.Hodes, S.A.Rosenberg, P.F.Robbins. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175:7046-52; PMID:16272366; http://dx.doi.org/10.4049/jimmunol.175.10.7046
49. A.Kalbasi, R.K.Shrimali, D.Chinnasamy, S.A.Rosenberg. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J Immunother 2010; 33:672-83; PMID:20664359; http://dx.doi.org/10.1097/CJI.0b013e3181e475cd
50. M.H.Kershaw, M.W.Teng, M.J.Smyth, P.K.Darcy. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5:928-40; PMID:16322746; http://dx.doi.org/10.1038/nri1729
51. W.N.Brennen, C.G.Drake, J.T.Isaacs. Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Res 2014; 74:3390-5; PMID:24747912; http://dx.doi.org/10.1158/0008-5472.CAN-14-0249
52. C.S.Hinrichs, Z.A.Borman, L.Gattinoni, Z.Yu, W.R.Burns, J.Huang, C.A.Klebanoff, L.A.Johnson, S.P.Kerkar, S.Yang et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808-14; PMID:20971955; http://dx.doi.org/10.1182/blood-2010-05-286286
53. M.Bellone, A.Calcinotto, A.Corti. Won't you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology 2012; 1:986-8; PMID:23162781; http://dx.doi.org/10.4161/onci.20213
54. N.Cieri, B.Camisa, F.Cocchiarella, M.Forcato, G.Oliveira, E.Provasi, A.Bondanza, C.Bordignon, J.Peccatori, F.Ciceri et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121:573-84; PMID:23160470; http://dx.doi.org/10.1182/blood-2012-05-431718
55. L.Gattinoni, C.A.Klebanoff, N.P.Restifo. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12:671-84; PMID:22996603; http://dx.doi.org/10.1038/nrc3322
56. E.Lugli, M.H.Dominguez, L.Gattinoni, P.K.Chattopadhyay, D.L.Bolton, K.Song, N.R.Klatt, J.M.Brenchley, M.Vaccari, Q.Gostickq et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013; 123(2):594-9; PMID:23281401; http://dx.doi.org/10.1172/JCI66327
57. L.Gattinoni, E.Lugli, Y.Ji, Z.Pos, C.M.Paulos, M.F.Quigley, J.R.Almeida, E.Gostick, Z.Yu, C.Carpenito et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
58. L.Galluzzi, E.Lugli. Rejuvenated T cells attack old tumors. Oncoimmunology 2013; 2:e24103; PMID:23526137; http://dx.doi.org/10.4161/onci.24103
59. R.P.Somerville, M.E.Dudley. Bioreactors get personal. Oncoimmunology 2012; 1:1435-7; PMID:23243620; http://dx.doi.org/10.4161/onci.21206
60. C.Wrzesinski, C.M.Paulos, A.Kaiser, P.Muranski, D.C.Palmer, L.Gattinoni, Z.Yu, S.A.Rosenberg, N.P.Restifo. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010; 33:1-7; PMID:19952961; http://dx.doi.org/10.1097/CJI.0b013e3181b88ffc
61. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
62. A.J.Montero, C.M.Diaz-Montero, C.E.Kyriakopoulos, V.Bronte, S.Mandruzzato. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107-15; PMID:22306898; http://dx.doi.org/10.1097/CJI.0b013e318242169f
63. S.Nagaraj, D.I.Gabrilovich. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348-53; PMID:20693846; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358
64. G.Cheng, A.Yu, T.R.Malek. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011; 241:63-76; PMID:21488890; http://dx.doi.org/10.1111/j.1600-065X.2011.01004.x
65. A.Y.Rudensky. Regulatory T cells and Foxp3. Immunol Rev 2011; 241:260-8; PMID:21488902; http://dx.doi.org/10.1111/j.1600-065X.2011.01018.x
66. X.Yao, M.Ahmadzadeh, Y.C.Lu, D.J.Liewehr, M.E.Dudley, F.Liu, D.S.Schrump, S.M.Steinberg, S.A.Rosenberg, P.F.Robbins. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012; 119:5688-96; PMID:22555974; http://dx.doi.org/10.1182/blood-2011-10-386482
67. K.N.Kodumudi, A.Weber, A.A.Sarnaik, S.Pilon-Thomas. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 2012; 189:5147-54; PMID:23100512; http://dx.doi.org/10.4049/jimmunol.1200274
68. H.Pere, C.Tanchot, J.Bayry, M.Terme, J.Taieb, C.Badoual, O.Adotevi, N.Merillon, E.Marcheteau, V.R.Quillien et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326-33; PMID:22737608; http://dx.doi.org/10.4161/onci.18852
69. L.Senovilla, I.Vitale, I.Martins, M.Tailler, C.Pailleret, M.Michaud, L.Galluzzi, S.Adjemian, O.Kepp, M.Niso-Santano et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
70. L.Gattinoni, S.E.Finkelstein, C.A.Klebanoff, P.A.Antony, D.C.Palmer, P.J.Spiess, L.N.Hwang, Z.Yu, C.Wrzesinski, D.M.Heimann et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
71. C.A.Klebanoff, H.T.Khong, P.A.Antony, D.C.Palmer, N.P.Restifo. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26:111-7; PMID:15668127; http://dx.doi.org/10.1016/j.it.2004.12.003
72. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
73. L.Galluzzi, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial Watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549
74. D.Alizadeh, M.Trad, N.T.Hanke, C.B.Larmonier, N.Janikashvili, B.Bonnotte, E.Katsanis, N.Larmonier. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 2014; 74:104-18; PMID:24197130; http://dx.doi.org/10.1158/0008-5472.CAN-13-1545
75. G.Mignot, E.Ullrich, M.Bonmort, C.Menard, L.Apetoh, J.Taieb, D.Bosisio, S.Sozzani, M.Ferrantini, J.Schmitz et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008; 180:6477-83; PMID:18453565; http://dx.doi.org/10.4049/jimmunol.180.10.6477
76. E.Ullrich, M.Bonmort, G.Mignot, B.Jacobs, D.Bosisio, S.Sozzani, A.Jalil, F.Louache, E.Bulanova, F.Geissman et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008; 180:7887-97; PMID:18523252; http://dx.doi.org/10.4049/jimmunol.180.12.7887
77. D.L.Liu, C.H.Hakansson, J.Seifert. Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis. Cancer Lett 1994; 85:39-46; PMID:7923100; http://dx.doi.org/10.1016/0304-3835(94)90236-4
78. M.W.Helms, J.A.Prescher, Y.A.Cao, S.Schaffert, C.H.Contag. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010; 59:1325-34; PMID:20532883; http://dx.doi.org/10.1007/s00262-010-0860-y
79. L.Galluzzi, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696
80. C.M.Paulos, A.Kaiser, C.Wrzesinski, C.S.Hinrichs, L.Cassard, A.Boni, P.Muranski, L.Sanchez-Perez, D.C.Palmer, Z.Yu et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13:5280-9; PMID:17875756; http://dx.doi.org/10.1158/1078-0432.CCR-07-1378
81. E.Vacchelli, L.Galluzzi, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931
82. Y.Yang, C.T.Huang, X.Huang, D.M.Pardoll. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5:508-15; PMID:15064759; http://dx.doi.org/10.1038/ni1059
83. L.Galluzzi, L.Senovilla, L.Zitvogel, G.Kroemer. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
84. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
85. S.Kan, S.Hazama, K.Maeda, Y.Inoue, S.Homma, S.Koido, M.Okamoto, M.Oka. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012; 32:5363-9; PMID:23225438
86. M.Tongu, N.Harashima, H.Monma, T.Inao, T.Yamada, H.Kawauchi, M.Harada. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383-91; PMID:22926062; http://dx.doi.org/10.1007/s00262-012-1343-0
87. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3: e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.9555691
88. Y.Ma, S.Adjemian, S.R.Mattarollo, T.Yamazaki, L.Aymeric, H.Yang, J.P.Portela Catani, D.Hannani, H.Duret, K.Steegh et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
89. J.Lee, S.H.Park, H.M.Chang, J.S.Kim, H.J.Choi, M.A.Lee, J.S.Jang, H.C.Jeung, J.H.Kang, H.W.Lee et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13:181-8; PMID:22192731; http://dx.doi.org/10.1016/S1470-2045(11)70301-1
90. D.D.Von Hoff, T.Ervin, F.P.Arena, E.G.Chiorean, J.Infante, M.Moore, T.Seay, S.A.Tjulandin, W.W.Ma, M.N.Saleh et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703; PMID:24131140; http://dx.doi.org/10.1056/NEJMoa1304369
91. S.A.Gujar, D.Clements, P.W.Lee. Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; http://dx.doi.org/10.4161/onci.27622
92. L.Galluzzi, I.Vitale, L.Senovilla, K.A.Olaussen, G.Pinna, T.Eisenberg, A.Goubar, I.Martins, J.Michels, G.Kratassiouk et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep.2012.06.017
93. L.Galluzzi, L.Senovilla, I.Vitale, J.Michels, I.Martins, O.Kepp, M.Castedo, G.Kroemer. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
94. M.Michaud, I.Martins, A.Q.Sukkurwala, S.Adjemian, Y.Ma, P.Pellegatti, S.Shen, O.Kepp, M.Scoazec, G.Mignot et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
95. W.Peng, G.Lizee, P.Hwu. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology 2013; 2:e22691; PMID:23524510; http://dx.doi.org/10.4161/onci.22691
96. L.Galluzzi, G.Kroemer, A.Eggermont. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3:e967147; PMID: 25941597; http://dx.doi.org/10.4161/21624011.2014.967147
97. L.B.John, M.H.Kershaw, P.K.Darcy. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013; 2:e26286; PMID:24353912; http://dx.doi.org/10.4161/onci.26286
98. R.P.Dings, K.B.Vang, K.Castermans, F.Popescu, Y.Zhang, M.G.Oude Egbrink, M.F.Mescher, M.A.Farrar, A.W.Griffioen, K.H.Mayo. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res 2011; 17:3134-45; PMID:21252159; http://dx.doi.org/10.1158/1078-0432.CCR-10-2443
99. R.K.Shrimali, Z.Yu, M.R.Theoret, D.Chinnasamy, N.P.Restifo, S.A.Rosenberg. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153
100. S.Mok, R.C.Koya, C.Tsui, J.Xu, L.Robert, L.Wu, T.G.Graeber, B.L.West, G.Bollag, A.Ribas. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014; 74:153-61; PMID:24247719; http://dx.doi.org/10.1158/0008-5472.CAN-13-1816
101. L.Senovilla, F.Aranda, L.Galluzzi, G.Kroemer. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014; 30C:24-31; PMID:24950501; http://dx.doi.org/10.1016/j.coi.2014.05.009
102. L.Senovilla, E.Vacchelli, J.Galon, S.Adjemian, A.Eggermont, W.H.Fridman, C.Sautès-Fridman, Y.Ma, E.Tartour, L.Zitvogel et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
103. H.Ledford. T-cell therapy extends cancer survival to years. Nature 2014; 516:156; PMID:25503214; http://dx.doi.org/10.1038/516156a
104. G.L.Beatty. Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. Oncoimmunology 2014; 3:e28327; PMID:25050204; http://dx.doi.org/10.4161/onci.28327
105. S.Yeh, N.K.Karne, S.P.Kerkar, C.K.Heller, D.C.Palmer, L.A.Johnson, Z.Li, R.J.Bishop, W.T.Wong, R.M.Sherry et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009; 116:981-9.e1; PMID:19410956; http://dx.doi.org/10.1016/j.ophtha.2008.12.004
106. R.A.Morgan, N.Chinnasamy, D.Abate-Daga, A.Gros, P.F.Robbins, Z.Zheng, M.E.Dudley, S.A.Feldman, J.C.Yang, R.M.Sherry et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
107. X.J.Xu, Y.M.Tang. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014; 343:172-8; PMID:24141191; http://dx.doi.org/10.1016/j.canlet.2013.10.004
108. R.A.Morgan. Risky business: target choice in adoptive cell therapy. Blood 2013; 122:3392-4; PMID:24235126; http://dx.doi.org/10.1182/blood-2013-09-527622
109. M.Ruella, M.Kalos. Adoptive immunotherapy for cancer. Immunol Rev 2014; 257:14-38; PMID:24329787; http://dx.doi.org/10.1111/imr.12136
110. S.L.Maude, D.Barrett, D.T.Teachey, S.A.Grupp. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20:119-22; PMID:24667956; http://dx.doi.org/10.1097/PPO.0000000000000035
111. D.T.Teachey, S.R.Rheingold, S.L.Maude, G.Zugmaier, D.M.Barrett, A.E.Seif, K.E.Nichols, E.K.Suppa, M.Kalos, R.A.Berg et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121:5154-7; PMID:23678006; http://dx.doi.org/10.1182/blood-2013-02-485623
112. H.J.Pegram, J.T.Jackson, M.J.Smyth, M.H.Kershaw, P.K.Darcy. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 2008; 181:3449-55; PMID:18714017; http://dx.doi.org/10.4049/jimmunol.181.5.3449
113. L.Ruggeri, M.Capanni, E.Urbani, K.Perruccio, W.D.Shlomchik, A.Tosti, S.Posati, D.Rogaia, F.Frassoni, F.Aversa et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science.1068440
114. A.Velardi, L.Ruggeri, A.Mancusi, F.Aversa, F.T.Christiansen. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21:525-30; PMID:19717293; http://dx.doi.org/10.1016/j.coi.2009.07.015
115. M.Ohira, H.Ohdan, H.Mitsuta, K.Ishiyama, Y.Tanaka, Y.Igarashi, T.Asahara. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006; 82:1712-9; PMID:17198265; http://dx.doi.org/10.1097/01.tp.0000250935.41034.2d
116. K.Okada, U.Nannmark, N.L.Vujanovic, S.Watkins, P.Basse, R.B.Herberman, T.L.Whiteside. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. Cancer Res 1996; 56:1599-608; PMID:8603408
117. M.J.Besser, T.Shoham, O.Harari-Steinberg, N.Zabari, R.Ortenberg, A.Yakirevitch, A.Nagler, R.Loewenthal, J.Schachter, G.Markel. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One 2013; 8:e57922; PMID:23483943; http://dx.doi.org/10.1371/journal.pone.0057922
118. M.Terme, W.H.Fridman, E.Tartour. NK cells from pleural effusions are potent antitumor effector cells. Eur J Immunol 2013; 43:331-4; PMID:23322344; http://dx.doi.org/10.1002/eji.201243264
119. J.Lister, W.B.Rybka, A.D.Donnenberg, M.deMagalhaes-Silverman, S.M.Pincus, E.J.Bloom, E.M.Elder, E.D.Ball, T.L.Whiteside. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995; 1:607-14; PMID:9816022
120. M.R.Parkhurst, J.P.Riley, M.E.Dudley, S.A.Rosenberg. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.1158/1078-0432.CCR-11-1347
121. E.G.Iliopoulou, P.Kountourakis, M.V.Karamouzis, D.Doufexis, A.Ardavanis, C.N.Baxevanis, G.Rigatos, M.Papamichail, S.A.Perez. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59:1781-9; PMID:20703455; http://dx.doi.org/10.1007/s00262-010-0904-3
122. C.Badoual, P.L.Bastier, H.Roussel, M.Mandavit, E.Tartour. An allogeneic NK cell line engineered to express chimeric antigen receptors: a novel strategy of cellular immunotherapy against cancer. Oncoimmunology 2013; 2:e27156; PMID:24753987; http://dx.doi.org/10.4161/onci.27156
123. L.Boissel, M.Betancur-Boissel, W.Lu, D.S.Krause, R.A.Van Etten, W.S.Wels, H.Klingemann. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:24404423; http://dx.doi.org/10.4161/onci.26527
124. B.Altvater, S.Landmeier, S.Pscherer, J.Temme, K.Schweer, S.Kailayangiri, D.Campana, H.Juergens, M.Pule, C.Rossig. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009; 15:4857-66; PMID:19638467; http://dx.doi.org/10.1158/1078-0432.CCR-08-2810
125. L.Boissel, M.Betancur, W.S.Wels, H.Tuncer, H.Klingemann. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009; 33:1255-9; PMID:19147228; http://dx.doi.org/10.1016/j.leukres.2008.11.024
126. P.Vacca, S.Martini, M.C.Mingari, L.Moretta. NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy? Oncoimmunology 2013; 2:e23638; PMID:23734317; http://dx.doi.org/10.4161/onci.23638
127. E.Vacchelli, L.Galluzzi, A.Eggermont, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer. Trial Watch: immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi.org/10.4161/onci.20459
128. E.Vacchelli, I.Martins, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/onci.22428
129. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, E.Tartour, L.Zitvogel, G.Kroemer et al. Trial Watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
130. J.H.Park, I.Riviere, X.Wang, S.Bartido, M.Sadelain, R.J.Brentjens. Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. ASCO Meeting Abstracts 2014; 32:7020
131. Y.Wang, W.Y.Zhang, Q.W.Han, Y.Liu, H.R.Dai, Y.L.Guo, J.Bo, H.Fan, Y.Zhang, Y.J.Zhang et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 2014; 155:160-75; PMID:25444722; http://dx.doi.org/10.1016/j.clim.2014.10.002
132. T.Chodon, B.Comin-Anduix, B.Chmielowski, R.C.Koya, Z.Wu, M.Auerbach, C.Ng, E.Avramis, E.Seja, A.Villanueva et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014; 20:2457-65; PMID:24634374; http://dx.doi.org/10.1158/1078-0432.CCR-13-3017
133. P.F.Robbins, S.H.Kassim, T.L.Tran, J.S.Crystal, R.A.Morgan, S.A.Feldman, J.C.Yang, M.E.Dudley, J.R.Wunderlich, R.M.Sherry et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-Reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 2015; 21:1019-27; PMID:25538264; http://dx.doi.org/10.1158/1078-0432.CCR-14-2708
134. L.A.Johnson, J.Scholler, T.Ohkuri, A.Kosaka, P.R.Patel, S.E.McGettigan, A.K.Nace, T.Dentchev, P.Thekkat, A.Loew et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7:275ra22; PMID:25696001; http://dx.doi.org/10.1126/scitranslmed.aaa4963
135. P.S.Adusumilli, L.Cherkassky, J.Villena-Vargas, C.Colovos, E.Servais, J.Plotkin, D.R.Jones, M.Sadelain. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6:261ra151; PMID:25378643; http://dx.doi.org/10.1126/scitranslmed.3010162
136. D.W.Lee, J.N.Kochenderfer, M.Stetler-Stevenson, Y.K.Cui, C.Delbrook, S.A.Feldman, T.J.Fry, R.Orentas, M.Sabatino, N.N.Shah et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385:517-28; PMID:25319501; http://dx.doi.org/10.1016/S0140-6736(14)61403-3
137. S.L.Maude, N.Frey, P.A.Shaw, R.Aplenc, D.M.Barrett, N.J.Bunin, A.Chew, V.E.Gonzalez, Z.Zheng, S.F.Lacey et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
138. I.Poschke, T.Lovgren, L.Adamson, M.Nystrom, E.Andersson, J.Hansson, R.Tell, G.V.Masucci, R.Kiessling. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 2014; 63:1061-71; PMID:24993563; http://dx.doi.org/10.1007/s00262-014-1575-2
139. E.Romano, O.Michielin, V.Voelter, J.Laurent, H.Bichat, A.Stravodimou, P.Romero, D.E.Speiser, F.Triebel, S.Leyvraz et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014; 12:97; PMID:24726012; http://dx.doi.org/10.1186/1479-5876-12-97
140. S.S.Chandran, B.C.Paria, A.K.Srivastava, L.D.Rothermel, D.J.Stephens, M.E.Dudley, R.Somerville, J.R.Wunderlich, R.M.Sherry, J.C.Yang. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res 2015; 21:534-43; PMID:25424856; http://dx.doi.org/10.1158/1078-0432.CCR-14-2208
141. A.P.Rapoport, N.A.Aqui, E.A.Stadtmauer, D.T.Vogl, Y.Y.Xu, M.Kalos, L.Cai, H.B.Fang, B.M.Weiss, A.Badros et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 2014; 20:1355-65; PMID:24520093; http://dx.doi.org/10.1158/1078-0432.CCR-13-2817
142. E.Tran, S.Turcotte, A.Gros, P.F.Robbins, Y.C.Lu, M.E.Dudley, J.R.Wunderlich, R.P.Somerville, K.Hogan, C.S.Hinrichs et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
143. J.Tseng, D.E.Citrin, M.Waldman, D.E.White, S.A.Rosenberg, J.C.Yang. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer 2014; 120:1426-32; PMID:24474396; http://dx.doi.org/10.1002/cncr.28547
144. A.Schuessler, C.Smith, L.Beagley, G.M.Boyle, S.Rehan, K.Matthews, L.Jones, T.Crough, V.Dasari, K.Klein et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 2014; 74:3466-76; PMID:24795429; http://dx.doi.org/10.1158/0008-5472.CAN-14-0296
145. G.Gallot, S.Vollant, S.Saiagh, B.Clemenceau, R.Vivien, E.Cerato, J.D.Bignon, C.Ferrand, A.Jaccard, S.Vigouroux et al. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study. J Immunother 2014; 37:170-9; PMID:24598452; http://dx.doi.org/10.1097/CJI.0000000000000031
146. R.Tell, J.Mattson, L.Adamson, I.Poschke, M.Engstrom, T.Lovgren, J.Hansson, G.V.Masucci, A.Lundqvist, R.Kiessling. A phase I study of adoptive T-cell therapy with or without dendritic cell vaccination in patients with metastatic melanoma. ASCO Meet Abstr 2014; 32:TPS3118
147. M.L.Disis, A.L.Coveler, D.Higgins, L.A.D'Amico, C.Morishima, J.R.Waisman, J.Reichow, J.Childs, Y.Dang, L.G.Salazar et al. Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2+ breast cancer. ASCO Meet Abstr 2014; 32:615
148. I.C.Glitza, C.Bernatchez, R.L.Bassett, C.Vaughn, P.Velasquez, A.Diab, R.N.Amaria, C.Yee, S.E.Woodman, S.P.Patel et al. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. ASCO Meeting Abstr 2014; 32:9079
149. C.S.Hinrichs, S.Stevanovic, L.Draper, R.Somerville, J.Wunderlich, N.P.Restifo, R.Sherry, P.Q.Giao, U.S.Kammula, J.C.Yang, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. ASCO Meet Abstr 2014; 32:LBA3008
150. Z.X.Wang, J.X.Cao, M.Wang, D.Li, Y.X.Cui, X.Y.Zhang, J.L.Liu, J.L.Li. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy 2014; 16:934-45; PMID:24794183; http://dx.doi.org/10.1016/j.jcyt.2014.02.011
151. M.J.Chung, J.Y.Park, S.Bang, S.W.Park, S.Y.Song. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother 2014; 63:939-46; PMID:24916038; http://dx.doi.org/10.1007/s00262-014-1566-3
152. S.B.Shi, X.Y.Tang, J.Tian, C.X.Chang, P.Li, J.L.Qi. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother 2014; 37:250-5; PMID:24714359; http://dx.doi.org/10.1097/CJI.0000000000000015
153. M.Killig, B.Friedrichs, J.Meisig, C.Gentilini, N.Bluthgen, C.Loddenkemper, M.Labopin, N.Basara, C.Pfrepper, D.W.Niederwieser et al. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation. Eur J Immunol 2014; 44:2822-34; PMID:24895051; http://dx.doi.org/10.1002/eji.201444586
154. H.Kimura, Y.Matsui, A.Ishikawa, T.Nakajima, M.Yoshino, Y.Sakairi. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother 2015; 64:51-9; PMID:25262164; http://dx.doi.org/10.1007/s00262-014-1613-0
155. J.G.Crompton, M.Sukumar, R.Roychoudhuri, D.Clever, A.Gros, R.L.Eil, E.Tran, K.Hanada, Z.Yu, D.C.Palmer et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 2015; 75:296-305; PMID:25432172; http://dx.doi.org/10.1158/0008-5472.CAN-14-2277
156. D.Geng, S.Kaczanowska, A.Tsai, K.Younger, A.Ochoa, A.P.Rapoport, S.Ostrand-Rosenberg, E.Davila. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res 2015; 75:1959-61; PMID:25795705; http://dx.doi.org/10.1158/0008-5472.CAN-14-2467
157. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
158. S.J.Gardai, K.A.McPhillips, S.C.Frasch, W.J.Janssen, A.Starefeldt, J.E.Murphy-Ullrich, D.L.Bratton, P.A.Oldenborg, M.Michalak, P.M.Henson. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123:321-34; PMID:16239148; http://dx.doi.org/10.1016/j.cell.2005.08.032
159. O.Kepp, L.Galluzzi, I.Martins, F.Schlemmer, S.Adjemian, M.Michaud, A.Q.Sukkurwala, L.Menger, L.Zitvogel, G.Kroemer. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61-9; PMID:21249425; http://dx.doi.org/10.1007/s10555-011-9273-4
160. D.R.Soto-Pantoja, M.Terabe, A.Ghosh, L.A.Ridnour, W.G.DeGraff, D.A.Wink, J.A.Berzofsky, D.D.Roberts. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 2014; 74:6771-83; PMID:25297630; http://dx.doi.org/10.1158/0008-5472.CAN-14-0037-T
161. L.Galluzzi, O.Kepp, G.Kroemer. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; PMID:24404424; http://dx.doi.org/10.4161/onci.26536
162. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
163. Y.H.Huang, C.Zhu, Y.Kondo, A.C.Anderson, A.Gandhi, A.Russell, S.K.Dougan, B.S.Petersen, E.Melum, T.Pertel et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015; 517:386-90; PMID:25363763; http://dx.doi.org/10.1038/nature13848
164. R.Lin, L.Chen, G.Chen, C.Hu, S.Jiang, J.Sevilla, Y.Wan, J.H.Sampson, B.Zhu, Q.J.Li. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest 2014; 124:5352-67; PMID:25347474; http://dx.doi.org/10.1172/JCI76561
165. I.Caruana, B.Savoldo, V.Hoyos, G.Weber, H.Liu, E.S.Kim, M.M.Ittmann, D.Marchetti, G.Dotti. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015; 21:524-9; PMID:25849134; http://dx.doi.org/10.1038/nm.3833
166. G.T.Motz, S.P.Santoro, L.P.Wang, T.Garrabrant, R.R.Lastra, I.S.Hagemann, P.Lal, M.D.Feldman, F.Benencia, G.Coukos. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20:607-15; PMID:24793239; http://dx.doi.org/10.1038/nm.3541
167. L.Galluzzi, J.M.Bravo-San Pedro, I.Vitale, S.A.Aaronson, J.M.Abrams, D.Adam, E.S.Alnemri, L.Altucci, D.Andrews, M.Annicchiarico-Petruzzelli et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22:58-73; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137
168. L.Galluzzi, J.M.Bravo-San Pedro, G.Kroemer. Organelle-specific initiation of cell death. Nat Cell Biol 2014; 16:728-36; PMID:25082195; http://dx.doi.org/10.1038/ncb3005
169. K.Kudo, C.Imai, P.Lorenzini, T.Kamiya, K.Kono, A.M.Davidoff, W.J.Chng, D.Campana. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 2014; 74:93-103; PMID:24197131; http://dx.doi.org/10.1158/0008-5472.CAN-13-1365
170. L.Galluzzi, E.Vacchelli, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, J.Zucman-Rossi, L.Zitvogel, G.Kroemer. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/onci.1.1.17938
171. E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
172. O.E.Okosieme, C.Evans, L.Moss, A.B.Parkes, L.D.Premawardhana, J.H.Lazarus. Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin Chem 2005; 51:729-34; PMID:15695326; http://dx.doi.org/10.1373/clinchem.2004.044511
173. M.Morishita, K.Uchimaru, K.Sato, A.Ohtsuru, S.Yamashita, T.Kanematsu, N.Yamashita. Thyroglobulin-pulsed human monocyte-derived dendritic cells induce CD4+ T cell activation. Int J Mol Med 2004; 13:33-9; PMID:14654967; http://dx.doi.org/10.3892/ijmm.13.1.33
174. A.L.Yu, A.L.Gilman, M.F.Ozkaynak, W.B.London, S.G.Kreissman, H.X.Chen, M.Smith, B.Anderson, J.G.Villablanca, K.K.Matthay et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
175. C.U.Louis, B.Savoldo, G.Dotti, M.Pule, E.Yvon, G.D.Myers, C.Rossig, H.V.Russell, O.Diouf, E.Liu et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6; PMID:21984804; http://dx.doi.org/10.1182/blood-2011-05-354449
176. N.K.Cheung, H.Guo, J.Hu, D.V.Tassev, I.Y.Cheung. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1:477-86; PMID:22754766; http://dx.doi.org/10.4161/onci.19864
177. M.Vincent, A.Quemener, Y.Jacques. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Oncoimmunology 2013; 2:e26441; PMID:24349876; http://dx.doi.org/10.4161/onci.26441
178. B.K.Choi, S.C.Lee, M.J.Lee, Y.H.Kim, Y.W.Kim, K.W.Ryu, J.H.Lee, S.M.Shin, S.H.Lee, S.Suzuki et al. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother 2014; 37:225-36; PMID:24714356; http://dx.doi.org/10.1097/CJI.0000000000000027
179. M.H.Kershaw, J.A.Westwood, C.Y.Slaney, P.K.Darcy. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology 2014; 3:e16; PMID:25505964; http://dx.doi.org/10.1038/cti.2014.7